Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
InMed Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
InMed Pharmaceuticals Gross Margin % Related Terms
InMed Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for InMed Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MWG vs SNOA, CVSI, PRFX: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InMed Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where InMed Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
InMed Pharmaceuticals (FRA:MWG) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on InMed Pharmaceuticals and its competitors. Over the past decade, InMed Pharmaceuticals' Gross Margin % has ranged from 23.95 to 80.34. According to the industry distribution chart, InMed Pharmaceuticals ranks #73 out of 938 companies in the Drug Manufacturers industry, placing it in the top 7.8%.
Is InMed Pharmaceuticals' Gross Margin % too high?
InMed Pharmaceuticals' current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 23.95 to a high of 80.34. Based on the distribution chart, InMed Pharmaceuticals ranks #73 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' Gross Margin % compare to SNOA and CVSI?
According to the Drug Manufacturers industry distribution chart, InMed Pharmaceuticals ranks #73 out of 938 companies for Gross Margin %. This places InMed Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Historically, InMed Pharmaceuticals' own Gross Margin % has ranged from 23.95 to 80.34 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on InMed Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InMed Pharmaceuticals's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
InMed Pharmaceuticals (FRA:MWG) has a current Gross Margin % of 0.00%. The stock's GF Value™ is €0.78, compared to a current price of €1.40 — trading 79.5% above its estimated fair value. The current Gross Margin % is 0.00%. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For InMed Pharmaceuticals (FRA:MWG), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InMed Pharmaceuticals (FRA:MWG) Overvalued in 2026?
Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued.
The current stock price of €1.40 is trading 79.5% above its estimated GF Value™ of €0.78.
Key valuation signals for FRA:MWG:
Gross Margin %: 0.00%
GF Value™: €0.78 vs. price of €1.40 (79.5% above fair value)
No single metric tells the full story. See the FRA:MWG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score
Get the complete analysis for FRA:MWG
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MWG has been successfully added to your 
